Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases

Gastroenterology

Volumn 152, Issue 2, 2017, Pages 362-373.e3

  Panes, Julian ^a   Jairath, Vipul ^b,c   Levesque, Barrett G ^c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Crohn's Disease; Outcomes; Prognostic Factor; Ulcerative Colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; LACTOFERRIN;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CROHN DISEASE; DIGESTIVE TRACT ENDOSCOPY; DISEASE ACTIVITY; DISEASE COURSE; GASTROINTESTINAL RADIOGRAPHY; HIGH RISK PATIENT; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE INJURY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PERIANAL ABSCESS; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ULCERATIVE COLITIS; CHEMISTRY; DIAGNOSTIC IMAGING; ECHOGRAPHY; FECES; INFLAMMATORY BOWEL DISEASES; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

BIOMARKERS; C-REACTIVE PROTEIN; ENDOSCOPY, DIGESTIVE SYSTEM; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 85007425654     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.10.005     Document Type: Article

References (119)

1. 1 Beaugerie, L., Seksik, P., Nion-Larmurier, I., et al. Predictors of Crohn's disease. Gastroenterology 130 (2006), 650–656.
2. 2 Loly, C., Belaiche, J., Louis, E., Predictors of severe Crohn's disease. Scand J Gastroenterol 43 (2008), 948–954.
3. 3 Dignass, A., Van Assche, G., Lindsay, J.O., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 4 (2010), 28–62.
4. 4 Dignass, A., Lindsay, J.O., Sturm, A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 6 (2012), 991–1030.
5. 5 Papay, P., Ignjatovic, A., Karmiris, K., et al. Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis 7 (2013), 653–669.
6. 6 Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
7. 7 Panes, J., O'Connor, M., Peyrin-Biroulet, L., et al. Improving quality of care in inflammatory bowel disease: what changes can be made today?. J Crohns Colitis 8 (2014), 919–926.
8. 8 Schreiber, S., Panes, J., Louis, E., et al. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol, 12, 2012, 108.
9. 9 Panes, J., Su, C., Bushmakin, A.G., et al. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol, 15, 2015, 14.
10. 10 Feagan, B.G., Hanauer, S.B., Coteur, G., et al. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther 33 (2011), 1143–1151.
11. 11 Higgins, P.D., Schwartz, M., Mapili, J., et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol 100 (2005), 355–361.
12. 12 Rutgeerts, P., Colombel, J., Schreiber, S., et al. Treatment of Crohn's disease (CD): response to Remicade (infliximab) in the ACCENT I trial through week 54. Am J Gastroenterol, 96, 2001, S303.
13. 13 Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
14. 14 Peyrin-Biroulet, L., Reinisch, W., Colombel, J.F., et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 63 (2014), 88–95.
15. 15 Khanna, R., Levesque, B.G., Bressler, B., et al. Early combined immunosuppression for the management of Crohn's disease: a community-based cluster randomized trial. J Crohns Colitis 8 (2014), S2–S3.
16. 16 Truelove, S.C., Witts, L.J., Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2 (1955), 1041–1048.
17. 17 Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 (1987), 1625–1629.
18. 18 Travis, S.P., Schnell, D., Krzeski, P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 61 (2012), 535–542.
19. 19 Feagan, B.G., Sandborn, W.J., D'Haens, G., et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 145 (2013), 149–157 e2.
20. 20 Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
21. 21 Sandborn, W., van Assche, G., Reinisch, W., et al. Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results. Gastroenterol Hepatol (N Y) 9 (2013), 317–320.
22. 22 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95 quiz e14–e15.
23. 23 Panaccione, R., Ghosh, S., Middleton, S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146 (2014), 392–400.e3.
24. 24 Colombel, J.F., Rutgeerts, P., Reinisch, W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141 (2011), 1194–1201.
25. 25 Kim, J.H., Cheon, J.H., Park, Y., et al. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 51 (2016), 1069–1074.
26. 26 Etchevers, M.J., Aceituno, M., Garcia-Bosch, O., et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis 15 (2009), 1320–1325.
27. 27 Farraye, F.A., Odze, R.D., Eaden, J., et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138 (2010), 746–774.
28. 28 Best, W.R., Becktel, J.M., Singleton, J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976), 439–444.
29. 29 Cellier, C., Sahmoud, T., Froguel, E., et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 35 (1994), 231–235.
30. 30 Rutgeerts, P., Van Assche, G., Sandborn, W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 142 (2012), 1102–1111 e2.
31. 31 Hebuterne, X., Lemann, M., Bouhnik, Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 62 (2013), 201–208.
32. 32 Khanna, R., Zou, G., D'Haens, G., et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut 65 (2016), 1119–1125.
33. 33 Hall, B., Holleran, G., Chin, J.L., et al. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. J Crohns Colitis 8 (2014), 1601–1609.
34. 34 Niv, E., Fishman, S., Kachman, H., et al. Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. J Crohns Colitis 8 (2014), 1616–1623.
35. 35 Panes, J., Bouhnik, Y., Reinisch, W., et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 7 (2013), 556–585.
36. 36 Annese, V., Daperno, M., Rutter, M.D., et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 7 (2013), 982–1018.
37. 37 D'Haens, G., Lowenberg, M., Samaan, M.A., et al. Safety and feasibility of using the second-generation pillcam colon capsule to assess active colonic Crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 1480–1486 e3.
38. 38 Levesque, B.G., Cipriano, L.E., Chang, S.L., et al. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol 8 (2010), 261–267 e1–4.
39. 39 Allez, M., Lemann, M., Bonnet, J., et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 97 (2002), 947–953.
40. 40 Enhanced algorithm for Crohn's treatment incorporating early combination therapy (REACT2). Available from: https://clinicaltrials.gov/ct2/show/NCT01698307. Accessed September 10, 2016.
41. 41 Pariente, B., Cosnes, J., Danese, S., et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 17 (2011), 1415–1422.
42. 42 Van Assche, G., Dignass, A., Panes, J., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 4 (2010), 7–27.
43. 43 Dignass, A., Eliakim, R., Magro, F., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 6 (2012), 965–990.
44. 44 Panes, J., Bouzas, R., Chaparro, M., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 34 (2011), 125–145.
45. 45 Gourtsoyiannis, N.C., Grammatikakis, J., Papamastorakis, G., et al. Imaging of small intestinal Crohn's disease: comparison between MR enteroclysis and conventional enteroclysis. Eur Radiol 16 (2006), 1915–1925.
46. 46 Oussalah, A., Laurent, V., Bruot, O., et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 59 (2010), 1056–1065.
47. 47 Punwani, S., Rodriguez-Justo, M., Bainbridge, A., et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 252 (2009), 712–720.
48. 48 Rimola, J., Rodriguez, S., Garcia-Bosch, O., et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 58 (2009), 1113–1120.
49. 49 Rimola, J., Ordas, I., Rodriguez, S., et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 17 (2011), 1759–1768.
50. 50 Makanyanga, J.C., Pendse, D., Dikaios, N., et al. Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol 24 (2014), 277–287.
51. 51 Albert, J.G., Martiny, F., Krummenerl, A., et al. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut 54 (2005), 1721–1727.
52. 52 Hyun, S.B., Kitazume, Y., Nagahori, M., et al. Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's disease. Inflamm Bowel Dis 17 (2011), 1063–1072.
53. 53 Sailer, J., Peloschek, P., Reinisch, W., et al. Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol 18 (2008), 2512–2521.
54. 54 Minordi, L.M., Scaldaferri, F., Marra, R.S., et al. Enterography CT without and with water enema in patients with Crohn's disease: results from a comparative observational study in comparison with endoscopy. Eur J Radiol 85 (2016), 404–413.
55. 55 Castiglione, F., Bucci, L., Pesce, G., et al. Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. Inflamm Bowel Dis 14 (2008), 1240–1245.
56. 56 Siddiki, H.A., Fidler, J.L., Fletcher, J.G., et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 193 (2009), 113–121.
57. 57 Ippolito, D., Invernizzi, F., Galimberti, S., et al. MR enterography with polyethylene glycol as oral contrast medium in the follow-up of patients with Crohn disease: comparison with CT enterography. Abdom Imaging 35 (2010), 563–570.
58. 58 Lee, S.S., Kim, A.Y., Yang, S.K., et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 251 (2009), 751–761.
59. 59 Fiorino, G., Bonifacio, C., Peyrin-Biroulet, L., et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis 17 (2011), 1073–1080.
60. 60 Martinez, M.J., Ripolles, T., Paredes, J.M., et al. Assessment of the extension and the inflammatory activity in Crohn's disease: comparison of ultrasound and MRI. Abdom Imaging 34 (2009), 141–148.
61. 61 Pascu, M., Roznowski, A.B., Muller, H.P., et al. Clinical relevance of transabdominal ultrasonography and magnetic resonance imaging in patients with inflammatory bowel disease of the terminal ileum and large bowel. Inflamm Bowel Dis 10 (2004), 373–382.
62. 62 Rimola, J., Panes, J., Ordas, I., Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials. Scand J Gastroenterol 50 (2015), 66–73.
63. 63 Ordas, I., Rimola, J., Rodriguez, S., et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 146 (2014), 374–382 e1.
64. 64 Absah, I., Bruining, D.H., Matsumoto, J.M., et al. MR enterography in pediatric inflammatory bowel disease: retrospective assessment of patient tolerance, image quality, and initial performance estimates. AJR Am J Roentgenol 199 (2012), W367–W375.
65. 65 Hordonneau, C., Buisson, A., Scanzi, J., et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn's disease: validation of quantitative index of activity. Am J Gastroenterol 109 (2014), 89–98.
66. 66 Drews, B.H., Barth, T.F., Hanle, M.M., et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. Eur Radiol 19 (2009), 1379–1386.
67. 67 Futagami, Y., Haruma, K., Hata, J., et al. Development and validation of an ultrasonographic activity index of Crohn's disease. Eur J Gastroenterol Hepatol 11 (1999), 1007–1012.
68. 68 Neye, H., Voderholzer, W., Rickes, S., et al. Evaluation of criteria for the activity of Crohn's disease by power Doppler sonography. Dig Dis 22 (2004), 67–72.
69. 69 Migaleddu, V., Scanu, A.M., Quaia, E., et al. Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. Gastroenterology 137 (2009), 43–52.
70. 70 Moreno, N., Ripolles, T., Paredes, J.M., et al. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with immunomodulators and/or anti-TNF antibodies. J Crohns Colitis 8 (2014), 1079–1087.
71. 71 Bell, S.J., Williams, A.B., Wiesel, P., et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 17 (2003), 1145–1151.
72. 72 Kamm, M.A., Ng, S.C., Perianal fistulizing Crohn's disease: a call to action. Clin Gastroenterol Hepatol 6 (2008), 7–10.
73. 73 Schwartz, D.A., Wiersema, M.J., Dudiak, K.M., et al. A prospective blinded comparison of endoscopic ultrasound (EUS), magnetic resonance imaging (MRI), and surgical examination under anesthesia (EUA) in the evaluation of perianal fistulas in patients with Crohn's disease (CD). Gastrointest Endosc, 53, 2001, AB69.
74. 74 Regueiro, M., Mardini, H., Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 9 (2003), 98–103.
75. 75 Haggett, P.J., Moore, N.R., Shearman, J.D., et al. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 36 (1995), 407–410.
76. 76 Bell, S.J., Halligan, S., Windsor, A.C., et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 17 (2003), 387–393.
77. 77 Van Assche, G., Vanbeckevoort, D., Bielen, D., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 98 (2003), 332–339.
78. 78 Horsthuis, K., Ziech, M.L., Bipat, S., et al. Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn's disease. Clin Imaging 35 (2011), 360–365.
79. 79 Savoye-Collet, C., Savoye, G., Koning, E., et al. Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis 17 (2011), 1751–1758.
80. 80 Tozer, P., Ng, S.C., Siddiqui, M.R., et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn's perianal fistulas. Inflamm Bowel Dis 18 (2012), 1825–1834.
81. 81 Gecse, K.B., Bemelman, W., Kamm, M.A., et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut 63 (2014), 1381–1392.
82. 82 Wise, P.E., Schwartz, D.A., The evaluation and treatment of Crohn perianal fistulae: EUA, EUS, MRI, and other imaging modalities. Gastroenterol Clin North Am 41 (2012), 379–391.
83. 83 Van Outryve, M.J., Pelckmans, P.A., Michielsen, P.P., et al. Value of transrectal ultrasonography in Crohn's disease. Gastroenterology 101 (1991), 1171–1177.
84. 84 Tio, T.L., Mulder, C.J., Wijers, O.B., et al. Endosonography of peri-anal and peri-colorectal fistula and/or abscess in Crohn's disease. Gastrointest Endosc 36 (1990), 331–336.
85. 85 Pariente, B., Mary, J.Y., Danese, S., et al. Development of the Lemann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology 148 (2015), 52–63 e3.
86. 86 Gilletta, C., Lewin, M., Bourrier, A., et al. Changes in the Lemann index values during the first years of Crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 1633–1640 e3.
87. 87 Fiorino, G., Bonifacio, C., Allocca, M., et al. Bowel damage as assessed by the lemann index is reversible on anti-TNF therapy for Crohn's disease. J Crohns Colitis 9 (2015), 633–639.
88. 88 Jauregui-Amezaga, A., Rimola, J., Ordas, I., et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn's disease in the era of biologics. Gut 64 (2015), 1397–1402.
89. 89 Ordás, I., Rimola, J., García-Bosch, O., et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 62 (2013), 1566–1572.
90. 90 Torres, J., Billioud, V., Peyrin-Biroulet, L., et al. Ulcerative colitis as a sole mucosal disease: another misunderstanding?. Gut, 61, 2012, 633.
91. 91 Pola, S., Patel, D., Ramamoorthy, S., et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol 10 (2012), 1315–1325 e4.
92. 92 Israeli, E., Ying, S., Henderson, B., et al. The impact of abdominal computed tomography in a tertiary referral centre emergency department on the management of patients with inflammatory bowel disease. Aliment Pharmacol Ther 38 (2013), 513–521.
93. 93 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
94. 94 Kathiresan, S., Larson, M.G., Vasan, R.S., et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 113 (2006), 1415–1423.
95. 95 Suk Danik, J., Chasman, D.I., Cannon, C.P., et al. Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet 70 (2006), 705–716.
96. 96 Siemons, L., Ten Klooster, P.M., Vonkeman, H.E., et al. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord, 15, 2014, 368.
97. 97 Lewis, J.D., C-reactive protein: anti-placebo or predictor of response. Gastroenterology 129 (2005), 1114–1116.
98. 98 Lundberg, J.O., Hellstrom, P.M., Fagerhol, M.K., et al. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005), 96–102.
99. 99 Roseth, A.G., Fagerhol, M.K., Aadland, E., et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 27 (1992), 793–798.
100. 100 Theede, K., Holck, S., Ibsen, P., et al. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis. Clin Gastroenterol Hepatol 13 (2015), 1929–1936 e1.
101. 101 Menees, S.B., Powell, C., Kurlander, J., et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 110 (2015), 444–454.
102. 102 Roseth, A.G., Aadland, E., Grzyb, K., Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39 (2004), 1017–1020.
103. 103 D'Haens, G., Ferrante, M., Vermeire, S., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18 (2012), 2218–2224.
104. 104 Lewis, J.D., The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 140 (2011), 1817–1826 e2.
105. 105 Mosli, M.H., Zou, G., Garg, S.K., et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110 (2015), 802–819.
106. 106 Lobaton, T., Lopez-Garcia, A., Rodriguez-Moranta, F., et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 7 (2013), e641–e651.
107. 107 Schoepfer, A.M., Beglinger, C., Straumann, A., et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 19 (2013), 332–341.
108. 108 Guidi, L., Marzo, M., Andrisani, G., et al. Faecal calprotectin assay after induction with anti-tumour necrosis factor alpha agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year. Dig Liver Dis 46 (2014), 974–979.
109. 109 Travis, S.P.L., Farrant, J.M., Ricketts, C., et al. Predicting the outcome in severe ulcerative colitis. Gut 38 (1996), 905–910.
110. 110 Carbonnel, F., Lavergne, A., Lemann, M., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 39 (1994), 1550–1557.
111. 111 Ho, G.T., Mowat, C., Goddard, C.J., et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 19 (2004), 1079–1087.
112. 112 Bryant, R.V., Burger, D.C., Delo, J., et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 65 (2016), 408–414.
113. 113 Xiong, Y., Wang, G.Z., Zhou, J.Q., et al. Serum antibodies to microbial antigens for Crohn's disease progression: a meta-analysis. Eur J Gastroenterol Hepatol 26 (2014), 733–742.
114. 114 Costa, F., Mumolo, M.G., Ceccarelli, L., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54 (2005), 364–368.
115. 115 Tibble, J.A., Sigthorsson, G., Bridger, S., et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119 (2000), 15–22.
116. 116 Osterman, M.T., Aberra, F.N., Cross, R., et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 12 (2014), 1887–1893 e3.
117. 117 Labaere, D., Smismans, A., Van Olmen, A., et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2 (2014), 30–37.
118. 118 Calafat, M., Cabre, E., Manosa, M., et al. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?. Inflamm Bowel Dis 21 (2015), 1072–1076.
119. 119 Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM) Available from: https://clinicaltrials.gov/ct2/show/NCT01235689. Accessed September 10, 2016.